NEW YORK (Reuters) - GlaxoSmithKline PLC (GSK.L) and Sanofi Aventis SA (SASY.PA) have emerged as bidders for Indian drug company Piramal Healthcare Ltd (PIRA.BO), with the sale price perhaps going as high as $1.5 billion, a source familiar with the situation said on Friday.
